Welldoc Bridges the Insulin Dosing Gap with New Real-World Evidence

Why It Matters

The modest TIR gains translate into clinically meaningful reductions in complications, supporting broader adoption of AI‑assisted dosing. Demonstrating real‑world effectiveness bolsters Welldoc’s position in the growing digital diabetes market.

Key Takeaways

• CGM-informed calculator raised TIR by 3.2% in three months
• Daily users saw 76% better outcomes than infrequent users
• Prior trial showed 3.8% TIR increase, 6.5% for type 2
• AI platform integrates with over 400 devices and EHR systems
• Welldoc holds 11 FDA clearances, 60 patents, strong evidence

Pulse Analysis

Managing insulin dosing remains one of the most complex tasks for people with type 1 and type 2 diabetes. Continuous glucose monitors provide real‑time data, yet translating those readings into accurate bolus decisions requires juggling carbohydrate counts, trend arrows, and activity levels. AI‑driven calculators simplify this process by automatically integrating multivariate inputs, reducing the error rate that historically affects roughly two‑thirds of manual calculations. As CGM adoption accelerates, tools that turn raw sensor data into actionable dosing recommendations are becoming essential components of modern diabetes care.

Welldoc’s latest real‑world evidence underscores the clinical value of such automation. In a cohort of 326 users, consistent use of the CGM‑informed bolus calculator lifted Time in Range by more than three percentage points—a threshold linked to lower risk of microvascular complications. Daily adopters experienced a 76% advantage over occasional users, echoing earlier trial results that showed even greater gains for type 2 patients without increasing hypoglycemia. These outcomes not only validate the algorithm’s accuracy but also demonstrate that sustained engagement can drive measurable health improvements at scale.

Beyond patient outcomes, the broader ecosystem stands to benefit. Welldoc’s platform interoperates with over 400 devices and integrates directly into electronic health records, facilitating seamless data flow for clinicians and payers. The company’s portfolio of FDA clearances and extensive patent portfolio positions it to capitalize on emerging reimbursement models that reward value‑based digital therapeutics. As health systems seek cost‑effective strategies to manage chronic disease, AI‑enhanced insulin dosing tools are poised to become a cornerstone of population health initiatives, driving both clinical and economic gains.